Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Medicare launched an 18-month pilot offering GLP-1 weight-loss drugs for just $50/month — but patients with conditions like sleep apnea or type 2 diabetes are being routed back to their Part D plans, where copays can run $200–$600/month. The cruel irony? Those with the greatest medical need are often the ones left out. Doctors say the program is failing its most vulnerable patients.
Medicare's GLP-1 Bridge program launched in July 2026, offering eligible Part D enrollees access to Wegovy, Zepbound KwikPen, and Foundayo for just $50/month — a landmark shift for a program long barred by law from covering weight-loss drugs. To qualify, beneficiaries need a BMI of 35+, or a BMI of 27+ with certain conditions like prediabetes or a prior heart attack. Most prior authorization requests have been completed in under 12 hours, and thousands have already accessed the drugs.
But there's a significant catch buried in the fine print: the $50 price applies only to those using GLP-1s solely for weight loss. Patients who have conditions the FDA has already approved GLP-1s to treat — like type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease — are ineligible for the Bridge discount and instead get routed back to their Part D plans, where costs can be far higher.
Key Takeaways:
Why it matters: Primary care physicians warn the Bridge program is paradoxically bypassing patients with the greatest medical need — those with multiple comorbidities who could benefit most from GLP-1 therapy. Until Congress acts to make coverage permanent and more inclusive, many of the sickest Medicare patients will remain priced out.
